Affordable Access

Thromboxane agonist (U46619) potentiates norepinephrine efflux from adrenergic nerves.

Authors
Type
Published Article
Journal
The Journal of pharmacology and experimental therapeutics
Publication Date
Volume
237
Issue
2
Pages
473–477
Identifiers
PMID: 3009787
Source
Medline
License
Unknown

Abstract

The effect of the synthetic thromboxane/prostaglandin (PG) H2 agonist U46619 on the electrically stimulated rabbit isolated was deferens was examined to test for thromboxane influences on adrenergic nerves. U46619 effects on force generation, [3H] norepinephrine release and norepinephrine-induced contractions were assessed to determine the mechanism of action. U46619 maximally enhanced adrenergic force generation 135 +/- 24% at a concentration of 100 nM. U46619 potentiated maximal contractile effects of exogenously administered norepinephrine 16 +/- 4% and augmented [3H]norepinephrine release from electrically stimulated preparations 142 +/- 44%. A competitive thromboxane/PGH2 receptor antagonist, SQ29548, significantly shifted the concentration-response curve for U46619 to the right in a concentration-dependent manner and blocked U46619-induced tritium release. Thus, U46619 appears to potentiate neurotransmitter release by interacting with thromboxane/PGH2 receptors. Because SQ29548 did not prevent the potentiation of norepinephrine contractions by U46619, the postjunctional effect may be independent of thromboxane/PGH2 receptors. We interpret these results to be indicative of both pre- and postjunctional sites of action of U46619. The physiological importance of these thromboxane effects is unknown currently.

Statistics

Seen <100 times